Further Expands Patient Access to Rosetta’s Differentiated Portfolio of Molecular Diagnostics including RosettaGX Reveal™ for the Classification of Indeterminate Thyroid Nodules

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces a new participation agreement with Preferred Provider Organization (PPO), Galaxy Health Network, as a preferred laboratory provider.

This new agreement, which covers more than 3.5 million members, increases Rosetta’s participation as a preferred provider to more than 166 million eligible contracted lives.

A PPO is a managed care organization of medical doctors, hospitals and other health care providers that has covenanted with an insurer or a third party administrator (TPA) to provide health care at reduced rates to the insurer's or administrator's clients.

“We are delighted to add Galaxy Health to our growing list of established health insurance providers. This agreement is expected to enhance both the timing and percentage of payments for our testing services, which is a critical success factor on our path to profitability,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “We look forward to working with the Galaxy Heath team and to continuing to execute additional agreements such as this in order to broaden access to our growing portfolio of molecular diagnostics and testing services.

“We are particularly pleased that this agreement will expand patient access for RosettaGX Reveal™, our first-of-its-kind microRNA classifier for indeterminate thyroid nodules. This new patient access should enhance our commercial and our reimbursement efforts both of which continue to gain significant traction in the fast-growing molecular classification market for indeterminate thyroid FNAs,” added Mr. Berlin.

About Galaxy Health Network

Galaxy Health Network, headquartered in Arlington, Texas, is a national managed care provider with over 3.5 million covered lives. Galaxy Health Network's Preferred Provider Organization includes a network of over 400,000 contracted physicians, 2,700 hospitals and 47,000 ancillary providers – all directly contracted, and brings together Managed Care Professionals with over five decades of collective experience for the purpose of providing expert assistance and guidance in the containment of medical costs.

About Rosetta Genomics

Rosetta develops and commercializes a full range of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company now offers core FISH, IHC and PCR-based testing capabilities and partnerships in Pathology, Oncology and Urology that provide additional content and platforms that complement Rosetta’s microRNA and Next-Gen Sequencing offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the diagnosis of indeterminate thyroid FNA smears, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs. For more information visit www.rosettagx.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to the enhancement of timing and percentage of payments received for our testing services, our profitability, our ability to add additional agreements and to broaden patient access to our portfolio, and our enhancement of our commercial and reimbursement efforts constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta GenomicsKen Berlin, 267-298-1159President & CEOinvestors@rosettagx.comorInvestors:LHAAnne Marie Fields, 212-838-3777afields@lhai.com

Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Rosetta Genomics (CE) Charts.
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Rosetta Genomics (CE) Charts.